reports
Atenor SA: 1 director
A director at Atenor SA bought 251,231 shares at 2.800EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
EVS EVS BROADCAST EQUIPMENT SA
UCB UCB S.A.
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
AED AEDIFICA SA
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- Mathijs Geerts Danau
Onward Medical Announces enrolment of first participant in Empower BP ...
Onward announces enrolment of the first participant in the Empower BP trial. The trial evaluates the ARC-IM system to address blood pressure instability in SCI patients. We note that Onward plans an interim analysis of the efficacy results in 2H26, which could accelerate timelines if fewer total patients are required. Short-term, we look forward to the FY25 results to gain a view on the ARC-EX commercial launch (9M25: 70 devices sold). We reiterate our € 8.9 TP and BUY rating.
- Wim Lewi
Elia Group German government agrees on 25.1% Tennet stake
Yesterday, the German government (via KfW) secured a 25.1% "blocking minority" in TenneT's German operations. The €3.3bn deal ends years of negotiations between Germany and the Netherlands. The deal is struck at the same equity value following the capital contribution (46%) from ABP, GIC and Norges Bank in 09/25 at a total equity value of 13.3bn. TenneT NL will hold the remaining 28.9%. We understand from the Handelsblatt that KfW will invest an additional €1.7bn before 2035. TenneT GE will no...
ONWARD Medical Announces First Participant Enrolled in Global Pivotal ...
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM® System to address blood pressure instability after spinal cord injury (SCI)Blood pressure instability is a key unmet need after SCI, with a significant impact on cardiovascular health and quality of lifeThe first participant was enrolled at Craig Hospital in Denver, Colorado, USA EINDHOVEN, the Netherlands, Feb. 04, ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Monitoring for a Pullback We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $257 on IWM (up from $245) continue to hold. We continue to see deterioration in market dynamics, and while we expect a period of consolidation/pullback, the afo...
GBX GREENBRIER COMPANIES INC.
TRN TRINITY INDUSTRIES INC.
TNET TRINET GROUP INC.
RHI ROBERT HALF INTERNATIONAL INC.
NSP INSPERITY INC.
KFY KORN FERRY
EURN EURONAV NV
LPG DORIAN LPG
G2O GOLAR LNG LIMITED
GATX GATX CORPORATION
KELYA KELLY SERVICES INC. CLASS A
KFRC KFORCE INC.
RAIL FREIGHTCAR AMERICA INC.
WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPORATION
FSTR L.B. FOSTER CO.
ASGN ASGN INC
STNG SCORPIO TANKERS INC.
FRO FRONTLINE PLC
TNK TEEKAY TANKERS LTD.
TBI TBI CORN LTD ORD
IBA – Share buyback
IBA – Share buyback Louvain-la-Neuve, Belgium, February 2nd, 2026 – 6PM CET – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today the launch of a share buyback program, effective as of February 3rd, 2026, in application of article 7:215 of the Belgian Companies and Associations Code. By a decision of the Board of Directors of March 18th, 2025, approving the Stock Option Plan 2025, and pursuant to the authorization given by the EGM of September 4th, 2023, IBA launched a program to buy back own shares through a mandate given to a...
IBA – Rachat d’Actions Propres
IBA – Rachat d’Actions Propres Louvain-la-Neuve, Belgique, 2 février 2026 – 18h00 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules, annonce aujourd’hui le lancement d’un programme de rachat d’actions propres à compter du 3 février 2026, en application de l’article 7:215 du Code belge des sociétés et des associations. Par une décision du Conseil d’administration du 18 mars 2025, approuvant le Plan de Stock-Options 2025, et conformément à l’autorisation donnée par l’AGE du 4 septembre 2023, IBA a lancé un programme de rachat d’actio...
- ING Helpdesk
Benelux Morning Notes
Adyen: New Platforms partnership in APAC / Dutch Pension Reform (Wtp): 1/3 transitioned (c.25 funds), 2027 challenging / IBA: Sale of a P1 system to MacKay Memorial Hospital in New Taipei City, Taiwan / KPN: 4Q25 preview / Offshore Wind: North Sea offshore wind pact to develop 300GW by 2050 / Vår Energi: RRR 2P 185% offsets slight pressure on expected production volumes 4Q
- Guy Sips
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
- Wim Lewi
Elia Group AI investment tsunami whips up TSO valuations
We upgrade our recommendation to Accumulate and raise our price target to €135.0 from €110.0 on multiple expansion over the next 6 to 12 months. We leave our EPS estimates for FY26-27 unchanged, but increase our price target to 22x FY27 EPS. Our previous target was based on 20x FY26 EPS, but we roll forward on a 10% higher multiple as the sentiment towards grid operators benefits from the “wall of money” into datacenters, while grid connection is the bottleneck. It can take years before the ROE ...
IBA signs contract for a Proteus®ONE proton therapy system to be locat...
IBA signs contract for a Proteus®ONE proton therapy system to be located at the MacKay Memorial Hospital in New Taipei City, Taiwan Louvain-La-Neuve, Belgium, January 27, 2026 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be installed at the MacKay Memorial Hospital in New Taipei City, Taiwan. This is the fourth order of a Proteus®ONE system in ...
IBA signe un contrat pour l’installation d’un système de protonthérapi...
IBA signe un contrat pour l’installation d’un système de protonthérapie Proteus®ONE au MacKay Memorial Hospital, à New Taipei City, Taïwan Louvain-la-Neuve, Belgique, le 27 janvier 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui avoir signé un contrat pour la fourniture d'une solution compacte de protonthérapie Proteus®ONE1 qui sera installée à l'hôpital MacKay Memorial de New Taipei City, à Taïwan. Il s'agit de la quatri...
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
- Mathijs Geerts Danau
Onward Medical Appoints Ali Kiboro as new CFO
Onward announced the appointment of a new CFO, Ali Kiboro. Mr. Kiboro brings more than 25 years of financial experience to Onward. He joins Onward from AliveDx where he served as Chief Financial Officer, leading the company's financial strategy, capital markets activities, and operational transformation. Prior to AliveDx, Ali held a variety of senior financial leadership roles at Quest Diagnostics and General Motors. Ali holds an MBA in Finance from The Wharton School and a Bachelor of Science i...
ONWARD Medical Appoints Ali Kiboro as Chief Financial Officer
ONWARD Medical Appoints Ali Kiboro as Chief Financial Officer EINDHOVEN, the Netherlands, Jan. 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, today announces the appointment of Ali Kiboro as Chief Financial Officer, effective January 2026. Ali brings more than 25 years of financial leadership experience across medical technology, tools and diagnostics, and general industry. He joins ONWARD Medical from AliveDx (formerly Quotient Lim...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thomas Couvreur
- Jacob Mekhael
Onward Medical Two additional BCI implants completed
Onward announced the successful 6th and 7th implants of its brain-computer interface (BCI) device in two additional spinal cord injury (SCI) patients, bringing the total number of human implants to seven. Onward's ARC-BCI effectively combines its proprietary implantable ARC-IM technology to affect movement and function with Clinatec's pioneering BCI device for thought-steered control, and we believe the joint technology could trigger a major step forward for patients suffering from spinal cord i...
ONWARD Medical Completes Two Additional Brain-Computer Interface Impla...
ONWARD Medical Completes Two Additional Brain-Computer Interface Implants Paired with Spinal Cord Stimulation Technology to Restore Thought-Driven Movement Investigational ARC-BCI® Therapy is being developed to restore thought-driven movement in people living with spinal cord injuries and other movement disabilitiesARC-BCI is the world’s first and most advanced purpose-designed platform pairing a brain-computer interface with an implantable spinal cord stimulation system Seven study participants have now received ARC-BCI Therapy to restore movement of their own paralyzed limbs EINDHOVEN, t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.